January 26, 2018 – Flagship is proud to partner with Summit Therapeutics in its efforts to advance therapies for patients with Duchenne Muscular Dystrophy (DMD). Summit Therapeutics issued a news release disclosing the interim results from its DMD phase II clinical trial, PhaseOut DMD. The endpoints reported by Flagship for these efforts are the first supporting evidence that ezutromid is having a positive impact on the patients in the study.
View the full news release or download the news release here.
Flagship Case Study: Multiplex Assays with Coregistration Enables Multiple Biomarker Analyses Across Tissue Sections